Quick answer: Perimenopause is the transition to menopause, with a boundary at each end that the specialists' staging system makes precise: it "begins at Stage –2 and ends 12 months after the FMP," the final menstrual period (Harlow et al., 2012) — meaning it starts when your cycle lengths turn persistently variable, and it is not over until a full year after your last bleed.
That second boundary is the part most consumer pages skip, and it is not a technicality: it changes when perimenopause is over and how long you need contraception. What follows is the definition in full, then a map of where each question that follows from it gets answered.
What perimenopause actually is
Perimenopause is the transitional phase leading up to menopause, during which ovarian function declines and the hormones that drive the menstrual cycle stop behaving predictably. It is defined by what your cycles are doing, not by how you feel.
It does not end at your last period. That is the force of the boundary quoted above, drawn from the Stages of Reproductive Aging Workshop +10 criteria — STRAW+10, the reference framework for staging reproductive aging. The twelve months of waiting needed to establish that a final period really was the final one is a stage in its own right, Stage +1a, and perimenopause does not close until the end of it (Harlow et al., 2012). So the entire first postmenopausal year sits inside perimenopause. It is common to see the transition described as ending when the bleeding stops; under STRAW+10 it doesn't.
The second thing worth straightening out is the word menopause itself. Menopause is not a phase — it is a single point in time, the final menstrual period, and it can only be identified in hindsight. As the National Institute on Aging puts it, you will only know you have reached it once you have gone a full year with no period or spotting (NIA). Everything before that point is perimenopause; everything after the 12-month mark is postmenopause. These get muddled constantly, which is why premenopause, perimenopause, menopause and postmenopause are worth setting out side by side on a page of their own.
And the mechanism underneath it all: hormone levels do not glide smoothly downward across these years. They swing. STRAW+10 describes the early transition as having "elevated but variable" follicle-stimulating hormone, and the late transition as involving "extreme fluctuations in hormonal levels" (Harlow et al., 2012). Erratic, not linear. Hold onto that, because it explains most of what follows — including why a single blood test is close to useless here.
Start here: where your question gets answered
The questions people arrive with here are genuinely different from one another, so each has a page of its own. The grouping below follows the order they tend to come up in. Each line is the short answer; the link goes to the page that works it through.
Noticing that something has changed
- The first sign and the most common sign are two different things — a change in cycle length comes first, while hot flashes are commonest overall — and no clinical body defines a fixed number of symptoms, so the signs worth paying attention to sorts them by how much each one actually tells you.
- Cycles usually shorten a little first, then start varying by a week or more, then start skipping, and flow often changes alongside the timing; a short list of bleeding patterns needs reporting rather than waiting out, which is the subject of how periods change, and which changes to get checked.
- Onset is usually in the mid- to late 40s, but three different ages get compressed into that one number and no age places you on its own. When it starts, when symptoms peak, and when it ends separates them.
Working out whether it really is this
- At 45 and over, no blood test confirms perimenopause and UK guidance tells clinicians not to order one; below 45 both the question and the answer change, which is the ground covered by what a test can and cannot settle.
- Thyroid disease, anaemia, depression, sleep apnoea, fibroids and several other conditions produce much the same week, and no symptom list separates them from perimenopause. The conditions that look like it sets out which test settles which.
Placing yourself, and knowing how long
- The transition has two stages inside it, early and late, both defined by what your cycles are doing rather than by your age or your symptoms, and perimenopause runs a stage longer than the transition does. The "four stages" version in circulation comes from a different research group's model, as where you are in the transition explains.
- Two clocks answer "how long", and they get quoted as though they were one: about four years for the transition itself, against a median of 7.4 years for frequent hot flashes and night sweats. How long it lasts, on both clocks also covers what eases once it is over.
- Three of the four terms — premenopause, perimenopause, postmenopause — name stretches of time, and menopause names a single day. What each of the four words means is the page for untangling them.
Deciding what to do
- There is no single best treatment, because the right one depends on which symptom is bothering you and what your own history allows, and the regulatory position moved in 2025 and 2026. The options by symptom, with evidence levels sets them out.
- Fertility in your forties is low, unpredictable and not zero, and the UK and US rules for when to stop contraception are not the same. Pregnancy and contraception in perimenopause gives the yearly odds by age band and both rules.
- No health body publishes a list of foods to avoid in perimenopause, and the two that address the question disagree with each other; where food changes something measurable is bone, cholesterol and muscle, which is where what to eat, and what the evidence supports concentrates.
- There is no evidence-based "top three" supplement: the two nutrients health bodies do single out for this stage, calcium and vitamin D, are named for bone rather than for symptoms, and a 2023 review of fifteen herbal products recommended none of them. Which supplements hold up goes through both aisles.
- In the largest study to measure this with body scans rather than a scale, the rate of weight gain did not change when women entered the transition; what changed was what the weight was made of, which is why the scale is the wrong instrument here is the place to start rather than a diet.
Reading a letter or a bill
- The code that gets used is N95.1, "Menopausal and female climacteric states", and no ICD-10-CM code is actually named perimenopause. The code on your notes explains why the answers you find conflict.
The stages, and how to tell where you are
The menopausal transition has two stages, early and late, and both are defined by your cycles rather than your age: STRAW+10 marks the early transition by a persistent difference of 7 days or more between the lengths of consecutive cycles, and the late transition by a stretch of 60 days or more with no period (Harlow et al., 2012). Perimenopause spans both of those and then a third stage, +1a — the 12 months it takes to establish that your final period really was the final one. Checking yourself against the two thresholds takes cycle lengths, first day of bleeding to first day of the next, which is why a paper calendar is a better instrument here than a blood test.
What "persistent" means, where the "four stages" you have probably seen come from, and which groups cannot be staged by their periods at all are covered in how each stage is defined, and how to place yourself.
When it usually starts, and how long it lasts
Most women begin the menopausal transition between ages 45 and 55 (NIA), and the Office on Women's Health puts the start of perimenopause in a woman's mid- to late 40s, while adding that "some women notice symptoms in their mid- to late 30s" (OWH). Cleveland Clinic describes the same wide window from the other end: as early as the mid-30s, as late as the mid-50s (Cleveland Clinic).
How long it then runs is a question on which two US sources openly differ, and the gap is wide enough to matter. Cleveland Clinic gives "about four years, but it can last up to eight years" (Cleveland Clinic). The Office on Women's Health agrees on the average and sets the ceiling higher: perimenopause "lasts about four years on average but can last up to 10 years leading into menopause" (OWH). We have not found a basis on which to prefer one ceiling over the other, so both are given. The much-repeated "two to eight years" is a third figure again, and it is not about the transition at all. It belongs to the NIA, and it describes symptoms: "symptoms related to menopause can last for between two and eight years" (NIA).
Now the average age of menopause, where the sources genuinely disagree. US federal health sources currently give 52 — "the average age of menopause is 52 in the United States" (NIA), a figure the Office on Women's Health also carries, alongside ages 45 to 55 as the span in which the transition into menopause usually happens rather than as a range for the final period itself (OWH). You will also see 51 cited very widely, including in clinical reference texts. We could not find a current US federal source that gives 51, so we use 52 throughout — but both numbers are genuinely in circulation, and flagging that is more useful to you than quietly picking a side.
One more distinction that gets blurred everywhere: how long the transition lasts and how long symptoms last are different questions with different answers. The transition averages about four years. Symptoms outlast it. In SWAN — the Study of Women's Health Across the Nation — 1,449 women with frequent hot flashes and night sweats had a median total duration of 7.4 years; among the 881 who had an observable final period, symptoms persisted a median of 4.5 years past it. For women whose symptoms started while they were still premenopausal or in early perimenopause, the median total duration was more than 11.8 years (Avis et al., 2015). Being premenopausal or early perimenopausal at onset was one of several characteristics the study tied to longer-lasting symptoms, alongside younger age, lower educational level, greater perceived stress and symptom sensitivity, and higher depressive symptoms and anxiety.
What actually changes
The defining sign is your cycle, not your temperature. Periods may come closer together or further apart, get heavier or lighter, or last longer or shorter than they used to — the NIA puts changes in your period first on its list, as the thing you may notice first (NIA).
Hot flashes and night sweats — vasomotor symptoms — are the best-known feature, and they are genuinely common: they occur in up to 80% of menopausal women, according to the 2023 nonhormone therapy position statement from The Menopause Society (The Menopause Society, 2023). Individual episodes usually run between 30 seconds and 10 minutes, and can arrive several times an hour or twice a week (NIA).
Then there is everything else: disrupted sleep, mood changes, vaginal dryness and urinary changes, and shifts in body composition. Two deserve flagging, because the usual explanation is imprecise. The first is cardiovascular: SWAN Heart data found that although triglycerides rose with age, "only total cholesterol, LDL-C and apoB showed a substantial increase specifically with menopause" — a change tied to the transition itself rather than to simply getting older, while HDL-C rose acutely before menopause and fell after (Woodard et al., 2011). That is the real reason midlife lipid screening matters; our guide to normal cholesterol levels by age covers what those numbers mean. The second is weight, where the standard "hormones make you gain weight" line turns out not to match what the DXA scans actually show — what body scans found instead changes what the problem even is. The symptom list as a whole runs far longer than this section, and the version worth reading is sorted by how much each sign actually tells you: the full symptom picture, ranked by evidence.
Why it happens
Ovarian function winds down. During the transition, in the NIA's words, "the body's production of estrogen and progesterone, two hormones made by the ovaries, declines greatly" (NIA) — and as it does, the feedback loop between the ovaries and the pituitary gland loses its rhythm. That is why FSH in the early transition is "elevated but variable" rather than simply high, and why the late transition involves "extreme fluctuations in hormonal levels" (Harlow et al., 2012). The swinging is the mechanism, not a side effect of it.
Here is the honest part, and it is more interesting than the confident version. The NIA states plainly that "it isn't clear why hot flashes are so common during the menopausal transition," while noting they are likely related to changing hormone levels (NIA). The working model centres on the brain's control of body temperature, and on a specific population of neurons involved in it.
You can see that model in what the newest drugs were built to do. The FDA describes fezolinetant as a neurokinin 3 receptor antagonist that "works to restore the balance between estrogen hormones and a brain chemical called neurokinin B (NKB) by blocking the activities of the NK3 receptor, which plays a role in the brain's control of body temperature" (FDA). Elinzanetant, approved in October 2025, is a dual NK1 and NK3 receptor antagonist; its FDA label states that blocking NK1 and NK3 signalling "on kisspeptin/neurokinin B/dynorphin (KNDy) neurons can modulate neuronal activity in thermoregulation associated with hot flashes" (FDA label, 2025). Note the word can: a mechanism the labels describe as drug-targetable, not a closed case.
How perimenopause is diagnosed, and why a blood test usually isn't the answer
For most women over 45, this is a clinical diagnosis made from age, symptoms and cycle history — not a lab test. Cleveland Clinic states it directly: "Hormone testing isn't necessary to diagnose perimenopause," and a provider may instead reach the conclusion "based on a physical exam and your symptoms, age and medical history" (Cleveland Clinic).
UK guidance says the same thing as an instruction rather than an observation, and it sets a visibly different bar from STRAW+10. NICE tells clinicians to identify, "without laboratory tests," in otherwise healthy women aged 45 or over who have menopause-associated symptoms, "perimenopause, if they have vasomotor symptoms that have recently started and any changes in their menstrual cycle" (NICE NG23, 1.3.1, last updated 15 April 2026). Note what that criterion does not ask for: no cycle-length arithmetic, no 60-day gap, no stage. The two frameworks answer different questions. STRAW+10 places you within the transition; NICE establishes that you are in it. For most women over 45 it is the second answer that changes what happens next.
The reason neither route needs a lab test is the one already established above, rather than a general hand-wave about hormones. STRAW+10 characterises early-transition FSH as "elevated but variable," and notes that in the late transition FSH levels are "sometimes elevated into the menopausal range and sometimes within the range characteristic of the earlier reproductive years" (Harlow et al., 2012). A single random draw samples one moment of a process whose defining feature is that it doesn't hold still. That is also the limitation of any test built on a single FSH reading.
Testing does have a role at the edges — the NIA notes a doctor may suggest a blood test to check hormone levels if, for example, periods stopped at an early age (NIA). Testing is the exception here, tied to unusually early onset — not the default route to an answer.
One thing that catches people reading their own after-visit summary: there is no ICD-10-CM code whose descriptor is "perimenopause." The code that gets used is N95.1, "Menopausal and female climacteric states," and it sits under a block header that does say "Menopausal and other perimenopausal disorders" — which is exactly why searching for it returns contradictory answers (AAPC, N95.1).
If what you want to know is whether to ask for a test at all, what a perimenopause test can and cannot settle sets out the case either way, including the situations where testing genuinely earns its place.
What can be done about it
Hormone therapy remains the most effective treatment for hot flashes and night sweats. The Menopause Society says so in both of its current statements, and the small difference between how they word it is worth a moment, because it decides who counts as a candidate. The 2023 nonhormone statement opens by saying that hormone therapy "remains the most effective treatment and should be considered in menopausal women aged younger than 60 years, within 10 years of their final menstrual periods, and without contraindications" (The Menopause Society, 2023), which reads as three conditions stacked together. The 2022 hormone therapy statement puts the same thing differently: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss" (The Menopause Society, 2022). There the age and the recency are alternatives, with only the absence of contraindications required alongside. That is not a quibble: on the 2022 wording a woman who is past 60 but within ten years of her final period is still inside the favourable window, and so is a woman under 60 who is further out than ten years. The 2023 statement's own abstract, incidentally, gives a third and shorter version, dropping age and keeping only "within 10 years of their final menstrual periods" (The Menopause Society, 2023). Whichever version you meet first, the decision is a clinical one that turns on your own history.
Non-hormonal prescription options exist too, and the regulatory ground under all of this has shifted four times since those statements were written, which is why pages on the subject date so quickly. The FDA added a Boxed Warning, its most prominent warning, to Veozah (fezolinetant) on 16 December 2024 for rare but serious liver injury, after a report of a patient with elevated liver blood tests and signs of liver injury about 40 days into treatment; prescribers now test liver function before starting and at intervals during treatment (FDA). Elinzanetant was approved in the US in October 2025 for moderate to severe vasomotor symptoms (FDA label, 2025), which is after every position statement in circulation, so no guideline grades it yet. On 10 November 2025 the FDA asked the companies marketing menopausal hormone therapy to remove the cardiovascular, breast-cancer and probable-dementia language, and "the recommendation to use the lowest effective dose for the shortest amount of time", from the Boxed Warning (FDA). That is a change in where risk information sits and how prominently, not a finding that the risks are gone. By 12 February 2026 it had "approved drug labeling changes to six menopausal hormone therapy products", with 29 companies having submitted proposals (FDA). And in England, NICE's appraisal of 31 March 2026 made fezolinetant an option "when hormone replacement therapy is unsuitable" (NICE TA1143). Option by option, with evidence levels and the UK–US splits, that is all in what the treatment options are and what has changed.
Then the lifestyle picture, which needs reading precisely. The same 2023 statement lists as not recommended supplements and herbal remedies (Levels I–II) and — at Level II — soy foods and soy extracts, the soy metabolite equol, exercise, yoga, mindfulness-based intervention, relaxation, acupuncture, cooling techniques and avoiding triggers, with dietary modification at Level III (The Menopause Society, 2023). Read that list precisely, because it is a list about one thing only: treating vasomotor symptoms. It is not a finding that exercise, yoga, mindfulness or a good diet are useless in perimenopause. The statement was evaluating one outcome — vasomotor symptoms — and did not assess these interventions for bone density, cardiovascular risk, mood, sleep or muscle mass, which is where the reasons to keep doing them actually come from. And in the very same document, weight loss is affirmatively recommended (Levels II–III) for vasomotor symptoms. Both halves are true at once, and dropping either one produces bad advice.
On the herbal side specifically, we have worked through the strongest available trial evidence for one of the most-asked-about options in our guide to ashwagandha for menopause, including where that evidence stops.
You can still get pregnant during perimenopause
Skipped periods are not contraception. The Office on Women's Health puts it in one line: "You can get pregnant during perimenopause, even if you skip periods" (OWH). Two things follow that catch people out. The first is that HRT is not contraception, and the NHS says exactly that, in those four words (NHS). Standard menopausal hormone therapy is neither licensed nor dosed to prevent pregnancy.
The second is that how long you keep using contraception depends on whose guidance you are reading, and the UK splits it by age. The NHS says you need it "for 1 year after your final period, if you're 50 or over" and "for 2 years after your final period, if you're aged 40 to 49 years old" (NHS, page last reviewed 19 May 2026). The NIA gives one rule at any age: birth control "for at least a full 12 months after her last period" (NIA). The yearly odds by age band sit on pregnancy and contraception during perimenopause, along with why one coil is treated differently from the rest.
When to see a doctor
Irregular periods are expected in perimenopause. These specific patterns are not, and the NIA lists them as reasons to see a doctor (NIA):
- Your periods happen very close together
- You have heavy bleeding
- You have bleeding or spotting after sex or between periods
- Your periods last more than a week
- You start bleeding or spotting again after not having a period for more than a year
Each of those is worth reporting rather than waiting out, and a fuller guide to bleeding changes in perimenopause explains what sits behind each one and how it is assessed.
One thing that list doesn't cover: symptoms starting before 40. That sits well outside the 45-to-55 window the NIA describes for the transition, and it is worth having properly assessed rather than waited out.
Common questions about perimenopause (FAQ)
What is the first sign of perimenopause? A change in the length of your cycles, not hot flashes. The clinical threshold for the early menopausal transition is a persistent difference of 7 days or more between the lengths of consecutive cycles — for example, a 27-day cycle followed by a 35-day one, with that variability recurring rather than happening once (Harlow et al., 2012).
What is the medical definition of perimenopause? Under the STRAW+10 staging criteria, perimenopause begins at the early menopausal transition — when cycle length becomes persistently variable — and ends 12 months after the final menstrual period (Harlow et al., 2012). It therefore includes the whole first postmenopausal year, not just the years of irregular bleeding.
Can you get pregnant during perimenopause? Yes. The Office on Women's Health states that you can get pregnant during perimenopause even if you skip periods (OWH), and the National Institute on Aging advises continuing birth control "for at least a full 12 months after her last period" if you don't want to conceive (NIA). Hormone therapy does not cover you: the NHS states that "HRT is not contraception" (NHS).
Is there a blood test for perimenopause? For most women over 45, no. Cleveland Clinic states that hormone testing isn't necessary to diagnose perimenopause (Cleveland Clinic), because the defining feature of the transition is hormonal variability — STRAW+10 describes early-transition FSH as "elevated but variable," so a single random draw can land anywhere (Harlow et al., 2012).
What age does perimenopause usually start? Most women begin the menopausal transition between ages 45 and 55 (NIA), and the Office on Women's Health describes perimenopause as usually starting in a woman's mid- to late 40s (OWH). Cleveland Clinic notes it can begin as early as the mid-30s or as late as the mid-50s (Cleveland Clinic).
Medical disclaimer: This article is for informational purposes only. Always consult a qualified healthcare provider before making changes to your health routine.
Sources
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause, 2012;19(4) — Peer-reviewed journal article via PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3340903/
- National Institute on Aging (NIH). What Is Menopause? — Government health information. https://www.nia.nih.gov/health/menopause/what-menopause
- Office on Women's Health, US Department of Health and Human Services. Menopause basics — Government health information. https://womenshealth.gov/menopause/menopause-basics
- Cleveland Clinic. Perimenopause — Health system disease reference. https://my.clevelandclinic.org/health/diseases/21608-perimenopause
- The North American Menopause Society (The Menopause Society). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 2023;30(6):573–590 — Position statement PDF. https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
- Avis NE, Crawford SL, Greendale G, et al. Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition. JAMA Internal Medicine, 2015 (SWAN) — Peer-reviewed journal article via PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC4433164/
- Woodard GA, Brooks MM, Barinas-Mitchell E, Mackey RH, Matthews KA, Sutton-Tyrrell K. Lipids, Menopause and Early Atherosclerosis in SWAN Heart Women. Menopause, 2011;18(4):376 — Peer-reviewed journal article via PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3123389/
- US Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Boxed Warning update posted 16 December 2024 — Drug Safety Communication. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
- US Food and Drug Administration. LYNKUET (elinzanetant) capsules, for oral use — Prescribing information, revised October 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219469s000lbl.pdf
- AAPC. ICD-10-CM code N95.1 — Menopausal and female climacteric states — Medical coding reference (FY2026 codes). https://www.aapc.com/codes/icd-10-codes/N95.1
- National Institute for Health and Care Excellence. Menopause: identification and management. NICE guideline NG23 — National clinical guideline. Published 12 November 2015, last updated 15 April 2026. Recommendation 1.3.1 is quoted. https://www.nice.org.uk/guidance/ng23/chapter/Recommendations
- NHS. Menopause and perimenopause — Symptoms — Government health information, page last reviewed 19 May 2026. https://www.nhs.uk/conditions/menopause-and-perimenopause/symptoms/
- NHS. Menopause and perimenopause — Things you can do — Government health information. https://www.nhs.uk/conditions/menopause-and-perimenopause/things-you-can-do/
- The North American Menopause Society (The Menopause Society). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022;29(7):767–794 — Position statement PDF. https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
- US Food and Drug Administration. FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies — Federal regulator drug alert, dated 10 November 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations
- US Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products — Press announcement, 12 February 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
- National Institute for Health and Care Excellence. Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause. Technology appraisal guidance TA1143 — National technology appraisal, published 31 March 2026. https://www.nice.org.uk/guidance/ta1143/chapter/1-Recommendation
Every source above was accessed or re-verified on 22 October 2026. Two were found to have changed since this page was first published, and the text has been corrected accordingly: the Office on Women's Health rewrote its menopause basics page on 19 October 2026, and the "most effective treatment" recommendation was traced to the correct position statement of the two.
Claire Whitfield
A women's health specialist who would rather read the actual staging criteria than a summary of a summary of them.
